Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib. Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.
Study Type
OBSERVATIONAL
Enrollment
77
David Ferreras
Murcia, Spain
KIT Gene mutation
Number of patients with a molecular analysis positive for KIT mutation
Time frame: 15 years
PDGFRA Gene mutation
Number of patients with a molecular analysis positive for PDGFRA mutation
Time frame: 15 years
Expression of CD117
Number of patients with immunohistochemical expression of CD117
Time frame: 15 years
Expression of DOG1
Number of patients with immunohistochemical expression of DOG1
Time frame: 15 years
Recurrence
Number of patients with recurrence after treatment with tyrosinkin inhibitors.
Time frame: 15 years
Deceased
Number of patients deceased during follow-up.
Time frame: 15 years
Location
Location of the tumor (gastric o jejunoileal)
Time frame: 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.